InNexus Biotechnology Inc. chose a well-validated target, CD20, to show that its second generation, conjugated monoclonal antibodies are more potent than first generation, unconjugated MAbs.

Last week, InNexus (TSX-V:IXS; IXSBF, Vancouver, B.C.) disclosed in vitro data showing that its DXL625 anti-CD20 MAb has greater potency than unconjugated MAbs, including an increased induction of apoptosis and complement dependent cytolysis (CDC), as well as greater inhibition of cell proliferation.